Abstract:Abstract Background: The effect and mechanism of Saccharomyces boulardii (Sb) in inflammatory bowel disease are unclear. The objective of the study was to evaluate the impact of Sb on intestinal mucosal barrier and intestinal flora in a colitis mouse model. Methods: Forty C57BL/6J male mice were randomly assigned to five groups: normal control group (A), pathologic control group (B), Sb treatment group (C), mesalazine treatment group (D), and Sb combined with mesalazine treatment group (E). Colitis was induced by the addition of 2.5% (wt/vol) dextran sodium sulfate (DSS) in the drinking water ad libitum for 7 days. The general condition, weight change, stool property, and bloody stool level of mice were observed to evaluate the disease activity index. The expression of zona occludens-1 (ZO-1) and occludin in intestinal tissue were measured by immunohistochemistry. The level of tumor necrosis factor-α (TNF-α) and interleukin (IL)-8 in plasma was measured by enzyme linked immunosorbent assay. Inter-cellular tight junctions were observed by transmission electron microscopy. The feces and intestinal contents were collected sterilely, and intestinal flora was analyzed by 16S rRNA sequencing. Results: Compared with group B, Sb reduced the disease activity index and histological score of group C (disease activity index: group B 2.708 ± 0.628, group C 1.542 ± 0.616, PBC = 0.005; histological score: group B 9.875 ± 3.271, group C 4.750 ± 1.832, PBC = 0.005) in DSS-induced colitis in mice. Sb exerted a protect effect on the expression of ZO-1 (group B 2.075 ± 1.176, group C 4.225 ± 1.316, PBC = 0.019) and occludin (group B 2.200 ± 0.968, group C 3.525 ± 1.047, PBC = 0.023). Compared with group B, Sb decreased the level of TNF-α and IL-8 of group C (TNF-α: group B 716.323 ± 44.691 ng/L, group C 521.740 ± 90.121 ng/L, PBC = 0.001; IL-8: group B 128.992 ± 11.475 pg/mL, group C 106.283 ± 15.906 pg/mL, PBC = 0.012). Treatment with Sb preserved the tight junctions and ameliorated microvilli and inter-cellular space. Treatment with Sb also showed its own characteristics: a higher percentage of Bacteroidetes and a lower percentage of Firmicutes, with significant differences or a significant trend. The proportion of the S24-7 family was increased significantly in the Sb treatment group. Conclusions: Sb shows an anti-inflammatory effect and has a protective effect on the intestinal mucosal mechanical barrier. Sb may up-regulate the abundance of family S24-7 specifically, and maybe a mechanism underlying its function.

Saccharomyces boulardii, a yeast probiotic, inhibits gut motility through upregulating intestinal serotonin transporter and modulating gut microbiota

Intestinal Crosstalk Between Microbiota and Serotonin and Its Impact on Gut Motility

Serotoninergic Mechanisms of Action in the Relaxant Properties of Saccharomyces boulardii CNCM I-745 on the Intestine

Small Intestinal Bacterial Overgrowth in Patients with Irritable Bowel Syndrome: Clinical Characteristics, Psychological Factors, and Peripheral Cytokines

Mucosal Serotonin Reuptake Transporter Expression in Irritable Bowel Syndrome Is Modulated by Gut Microbiota Via Mast Cell-Prostaglandin E2

Saccharomyces Boulardiicncm I-745 Modulates The Microbiota-Gut-Brain Axis In A Humanized Mouse Model Of Irritable Bowel Syndrome

The Effects of Saccharomyces Boulardii on Rat Colonic Hypermotility Induced by Repeated Water Avoidance Stress and the Potential Mechanism.

Effect of Bacillus Subtilis, Enterococcus Faecium, and Enterococcus Faecalis Supernatants on Serotonin Transporter Expression in Cells and Tissues.

Saccharomyces boulardii CNCM I-745 supplementation reduces gastrointestinal dysfunction in an animal model of IBS

Protective Effect of Saccharomyces Boulardii on Intestinal Mucosal Barrier of Dextran Sodium Sulfate-Induced Colitis in Mice

TRIM21 Negatively Regulates Intestinal Mucosal Inflammation Through Inhibition of Th1/Th17 Cell Immune Responses in Inflammatory Bowel Disease

<i>Saccharomyces boulardii</i> alleviates DSS-induced intestinal barrier dysfunction and inflammation in humanized mice

Bifidobacterium bifidum CCFM1359 alleviates intestinal motility disorders through the BDNF-TrkB pathway

Bifico relieves irritable bowel syndrome by regulating gut microbiota dysbiosis and inflammatory cytokines

Regulation of the serotonin transporter in the pathogenesis of irritable bowel syndrome.

Saccharomyces boulardii protects against murine experimental colitis by reshaping the gut microbiome and its metabolic profile

Saccharomyces boulardii ameliorates gut dysbiosis associated cognitive decline

Effect of probiotic bacteria on the intestinal microbiota in irritable bowel syndrome.

Effect of Lactobacillus Rhamnosus GG Supernatant on Serotonin Transporter Expression in Rats with Post-Infectious Irritable Bowel Syndrome.

Lactobacillus Acidophilus and Bifidobacterium Longum Supernatants Upregulate the Serotonin Transporter Expression in Intestinal Epithelial Cells.

Aggregation and Self-Assembly of Hydrophobins from Trichoderma Reesei: Low-Resolution Structural Models